Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit.

Lythgoe, Mark P; Krell, Jonathan; Bower, Mark; Murphy, Ravindhi; Marriott, John; Blagden, Sarah P; Aggarwal, Ajay; Sullivan, Richard.

Lancet Oncol ; 24(4): e150-e160, 2023 04.

Artículo en Inglés | MEDLINE | ID: mdl-36990613

2.

Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.

Blagden, Sarah P; Yu, Ly-Mee; Ellis, Stephanie; Hughes, Helen; Shaaban, Abeer; Fennelly-Barnwell, Jonathan; Lythgoe, Mark P; Cooper, Alison M; Maignen, Francois M; Buckland, Sean W; Kearns, Pamela R; Brown, Louise C.

Br J Cancer ; 128(3): 474-477, 2023 02.

Artículo en Inglés | MEDLINE | ID: mdl-36434156

3.

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.

Luke, Jason J; Fakih, Marwan; Schneider, Charles; Chiorean, E Gabriela; Bendell, Johanna; Kristeleit, Rebecca; Kurzrock, Razelle; Blagden, Sarah P; Brana, Irene; Goff, Laura W; O'Hayer, Kevin; Geschwindt, Ryan; Smith, Michael; Zhou, Feng; Naing, Aung.

Br J Cancer ; 128(12): 2227-2235, 2023 06.

Artículo en Inglés | MEDLINE | ID: mdl-37087488

4.

Controversies around the function of LARP1.

Berman, Andrea J; Thoreen, Carson C; Dedeic, Zinaida; Chettle, James; Roux, Philippe P; Blagden, Sarah P.

RNA Biol ; 18(2): 207-217, 2021 02.

Artículo en Inglés | MEDLINE | ID: mdl-32233986

5.

LARP1 isoform expression in human cancer cell lines.

Schwenzer, Hagen; Abdel Mouti, Mai; Neubert, Pia; Morris, Josephine; Stockton, Joanne; Bonham, Sarah; Fellermeyer, Martin; Chettle, James; Fischer, Roman; Beggs, Andrew D; Blagden, Sarah P.

RNA Biol ; 18(2): 237-247, 2021 02.

Artículo en Inglés | MEDLINE | ID: mdl-32286153

6.

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.

Blagden, Sarah P; Cook, Adrian D; Poole, Christopher; Howells, Lesley; McNeish, Ian A; Dean, Andrew; Kim, Jae-Weon; O'Donnell, Dearbhaile M; Hook, Jane; James, Elizabeth C; White, Ian R; Perren, Timothy; Lord, Rosemary; Dark, Graham; Earl, Helena M; Hall, Marcia; Kaplan, Richard; Ledermann, Jonathan A; Clamp, Andrew R.

Lancet Oncol ; 21(7): 969-977, 2020 07.

Artículo en Inglés | MEDLINE | ID: mdl-32615110

7.

Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.

Blagden, Sarah P; Billingham, Lucinda; Brown, Louise C; Buckland, Sean W; Cooper, Alison M; Ellis, Stephanie; Fisher, Wendy; Hughes, Helen; Keatley, Debbie A; Maignen, Francois M; Morozov, Alex; Navaie, Will; Pearson, Sarah; Shaaban, Abeer; Wydenbach, Kirsty; Kearns, Pamela R.

Br J Cancer ; 122(4): 473-482, 2020 02.

Artículo en Inglés | MEDLINE | ID: mdl-31907370

8.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Mak, Gabriel; Soria, Jean-Charles; Blagden, Sarah P; Plummer, Ruth; Fleming, Ronald A; Nebot, Noelia; Zhang, Jianping; Mazumdar, Jolly; Rogan, Debra; Gazzah, Anas; Rizzuto, Ivana; Greystoke, Alastair; Yan, Li; Tolson, Jerry; Auger, Kurt R; Arkenau, Hendrik-Tobias.

Br J Cancer ; 120(10): 975-981, 2019 05.

Artículo en Inglés | MEDLINE | ID: mdl-30992546

9.

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.

Blagden, Sarah P; Rizzuto, Ivana; Suppiah, Puvan; O'Shea, Daniel; Patel, Markand; Spiers, Laura; Sukumaran, Ajithkumar; Bharwani, Nishat; Rockall, Andrea; Gabra, Hani; El-Bahrawy, Mona; Wasan, Harpreet; Leonard, Robert; Habib, Nagy; Ghazaly, Essam.

Br J Cancer ; 119(7): 815-822, 2018 10.

Artículo en Inglés | MEDLINE | ID: mdl-30206366

10.

Targeting MAPK in recurrent, low-grade serous ovarian cancer.

Blagden, Sarah P.

Lancet ; 399(10324): 499-501, 2022 02 05.

Artículo en Inglés | MEDLINE | ID: mdl-35123677

11.

The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.

Hopkins, Thomas G; Mura, Manuela; Al-Ashtal, Hiba A; Lahr, Roni M; Abd-Latip, Normala; Sweeney, Katrina; Lu, Haonan; Weir, Justin; El-Bahrawy, Mona; Steel, Jennifer H; Ghaem-Maghami, Sadaf; Aboagye, Eric O; Berman, Andrea J; Blagden, Sarah P.

Nucleic Acids Res ; 44(3): 1227-46, 2016 Feb 18.

Artículo en Inglés | MEDLINE | ID: mdl-26717985

12.

A source of hope for platinum-resistant ovarian cancer?

Blagden, Sarah P; Nicum, Shibani.

Lancet ; 397(10271): 254-256, 2021 01 23.

Artículo en Inglés | MEDLINE | ID: mdl-33485431

13.

The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5'TOP sequence.

Lahr, Roni M; Mack, Seshat M; Héroux, Annie; Blagden, Sarah P; Bousquet-Antonelli, Cécile; Deragon, Jean-Marc; Berman, Andrea J.

Nucleic Acids Res ; 43(16): 8077-88, 2015 Sep 18.

Artículo en Inglés | MEDLINE | ID: mdl-26206669

14.

A decade of LARP society.

Blagden, Sarah P; Bayfield, Mark; Bousquet-Antonelli, Cecile.

RNA Biol ; 18(2): 157-158, 2021 02.

Artículo en Inglés | MEDLINE | ID: mdl-33651971

15.

Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.

Rizzuto, Ivana; Stavraka, Chara; Chatterjee, Jayanta; Borley, Jane; Hopkins, Thomas Glass; Gabra, Hani; Ghaem-Maghami, Sadaf; Huson, Les; Blagden, Sarah P.

Int J Gynecol Cancer ; 25(3): 416-22, 2015 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-25647256

16.

Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.

Stavraka, Chara; Pinato, David J; Turnbull, Samantha J; Flynn, Michael J; Forster, Martin D; O'Cathail, Sean M; Babar, Sayed; Seckl, Michael J; Kristeleit, Rebecca S; Blagden, Sarah P.

Cancer ; 120(2): 262-70, 2014 Jan 15.

Artículo en Inglés | MEDLINE | ID: mdl-24399418

17.

New challenges in psycho-oncology: Using drug development methodology to improve survivorship and supportive care intervention trials.

Howells, Lesley; Hulbert-Williams, Nicholas J; Blagden, Sarah P.

Psychooncology ; 28(7): 1362-1366, 2019 07.

Artículo en Inglés | MEDLINE | ID: mdl-31106934

18.

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.

Janku, Filip; Choong, Grace M; Opyrchal, Mateusz; Dowlati, Afshin; Hierro, Cinta; Rodon, Jordi; Wicki, Andreas; Forster, Martin D; Blagden, Sarah P; Yin, Jun; Reid, Joel M; Muller, Helene; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Adjei, Alex A.

Cancers (Basel) ; 16(6)2024 Mar 13.

Artículo en Inglés | MEDLINE | ID: mdl-38539472

19.

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

Spiliopoulou, Pavlina; Kazmi, Farasat; Aroldi, Francesca; Holmes, Thomas; Thompson, David; Griffiths, Lucinda; Qi, Cathy; Parkes, Matthew; Lord, Simon; Veal, Gareth J; Harrison, David J; Coyle, Vicky M; Graham, Jill; Jeffry Evans, Thomas R; Blagden, Sarah P.

J Exp Clin Cancer Res ; 43(1): 100, 2024 Apr 02.

Artículo en Inglés | MEDLINE | ID: mdl-38566164

20.

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.

Dixon-Zegeye, Miriam; Shaw, Rachel; Collins, Linda; Perez-Smith, Kendra; Ooms, Alexander; Qiao, Maggie; Pantziarka, Pan; Izatt, Louise; Tischkowitz, Marc; Harrison, Rachel E; George, Angela; Woodward, Emma R; Lord, Simon; Hawkes, Lara; Evans, D Gareth; Franklin, James; Hanson, Helen; Blagden, Sarah P.

Trials ; 25(1): 103, 2024 Feb 03.

Artículo en Inglés | MEDLINE | ID: mdl-38308321

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: